LOS ANGELES, March 31, 2026
Trethera Corporation has announced a strategic clinical collaboration with Massachusetts General Hospital to evaluate its investigational therapy TRE-515 in patients with advanced amyotrophic lateral sclerosis (ALS) under the U.S. FDA Expanded Access program, marking a significant advancement in the pursuit of innovative treatments for this devastating neurodegenerative disease. The collaboration will enroll up to six patients and aims to generate critical insights into the safety, tolerability, and biological activity of TRE-515, a first-in-class inhibitor of deoxycytidine kinase (dCK), a key enzyme linked to inflammation and abnormal cellular signaling pathways increasingly implicated in ALS progression.
Novel Mechanism Targets Inflammation in ALS
TRE-515 represents a unique therapeutic approach in ALS by targeting nucleotide metabolism and inflammatory signaling, diverging from traditional symptomatic treatments. By inhibiting dCK, TRE-515 may reduce abnormal immune activation and cellular stress pathways that contribute to motor neuron degeneration. Emerging scientific evidence highlights the role of chronic inflammation in ALS pathology, positioning TRE-515 as a promising candidate to potentially modify disease progression rather than simply manage symptoms.
The trial at MGH will focus on advanced ALS patients, a population with urgent unmet medical needs. Participants will undergo monthly clinical evaluations, including ALS Functional Rating Scale-Revised (ALSFRS-R) and Slow Vital Capacity (SVC) assessments, alongside advanced biomarker monitoring such as neurofilament light chain (NfL). This integrated clinical and biomarker-driven approach is expected to provide valuable data on disease trajectory and drug mechanism, potentially guiding future patient selection and larger-scale clinical trials.
Clinical Collaboration Strengthens ALS Research Efforts
Advertisement
The study is led by Dr. Merit Cudkowicz, a globally recognized leader in ALS research and Executive Director of the Massachusetts General Brigham Neuroscience Institute. Under her leadership, MGH has established itself as a premier center for ALS clinical trials, accelerating the development of next-generation therapies. This collaboration reflects a growing trend of partnerships between biopharma innovators and leading academic institutions to fast-track therapeutic breakthroughs in complex neurological diseases.
Trethera’s leadership emphasized that the collaboration builds on encouraging early clinical findings observed in prior Expanded Access use. Notably, a previously treated patient with advanced ALS demonstrated disease stabilization, with a significant reduction in the rate of lung function decline and reported improvements in muscle strength and vocalization, without any treatment-related adverse events. While limited to a single case, these findings provide important preliminary evidence supporting further investigation of TRE-515 in ALS.
Early Data Signals Potential Breakthrough Opportunity
TRE-515’s favorable safety profile and selective mechanism of action have generated optimism among researchers and clinicians. Experts, including Dr. Lawrence Steinman of Stanford University, have highlighted the therapy’s potential to modulate inflammation with precision, a key factor in neurodegenerative disease progression. Although the current study is small, a positive clinical readout could pave the way for expanded trials and accelerated development pathways, particularly given the limited treatment landscape for ALS.
ALS remains a progressive and fatal neurodegenerative disorder, typically leading to death within two to five years of diagnosis. Despite ongoing research, effective disease-modifying therapies remain scarce, underscoring the urgency for innovative approaches like TRE-515. The collaboration between Trethera and MGH represents a critical step toward addressing this unmet need, combining cutting-edge science, clinical expertise, and patient-focused research frameworks.
As Trethera continues to advance TRE-515 across multiple indications, including cancer and autoimmune diseases, its application in ALS highlights the versatility of targeting metabolic pathways in complex diseases. With regulatory support such as Fast Track and Orphan Drug designations in other indications, TRE-515 is emerging as a high-potential asset in precision medicine. The outcomes of this collaboration could significantly influence the future direction of ALS treatment and reinforce the role of innovative metabolic therapies in neurodegenerative disease management.
Source: Trethera press release
